cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis成本效用分析英夫利昔单抗和adalimumab难治性溃疡性结肠炎.pdfVIP

  • 9
  • 0
  • 约5.51万字
  • 约 8页
  • 2017-09-06 发布于上海
  • 举报

cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis成本效用分析英夫利昔单抗和adalimumab难治性溃疡性结肠炎.pdf

cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis成本效用分析英夫利昔单抗和adalimumab难治性溃疡性结肠炎

Cost Effectiveness and Resource Allocation BioMed Central Research Open Access Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis 1,2 1,2 1,2 2 Feng Xie* , Gord Blackhouse , Nazi

您可能关注的文档

文档评论(0)

1亿VIP精品文档

相关文档